Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
Minimed GroupAbbVie
Last price
$18.28$294.89
Currency
USD
USD
$5.1B$521B
-50.77
-$1.19$5.81
--
0$6.83
02.35%
Sector
HealthHealth
Employees
-57,000
Ticker
$MMED$ABBV
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $MMED or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.